Design, synthesis and evaluation of isoxazolo[5,4-d]pyrimidin-4(5H)-one derivatives as antithrombotic agents

被引:6
作者
Yang, Jiabin [1 ]
Su, Guoqiang [2 ]
Ren, Yu [2 ]
Chen, Yang [1 ]
机构
[1] Southeast Univ, Sch Biol Sci & Med Engn, State Key Lab Bioelect, Nanjing 210096, Jiangsu, Peoples R China
[2] Nanjing Zhongrui Pharmaceut Co Ltd, Nanjing 211100, Jiangsu, Peoples R China
基金
中国国家自然科学基金;
关键词
Antithrombotic agent; Factor Xa; Isoxazolo[5,4-d]pyrimidin-4(5H)-one; Docking; FACTOR XA INHIBITORS; COAGULATION FACTOR XA; ORALLY BIOAVAILABLE INHIBITOR; HIGHLY POTENT; ISOXAZOLINE DERIVATIVES; VENOUS THROMBOEMBOLISM; DISCOVERY; ANTICOAGULANTS; THROMBIN; DX-9065A;
D O I
10.1016/j.bmcl.2014.12.039
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of isoxazolo[5,4-d]pyrimidin-4(5H)-one derivatives have been designed and synthesized as novel antithrombotic agents. The 4-acetoxyl substituted derivative (6g) displays very strong FXa inhibitory activity (IC50 = 0.013 mu M), excellent anticoagulant effect in human plasma (2 x PT = 2.12 mu M) and high selectivity to thrombin and trypsin. Docking investigation of 6g with FXa protein revealed that the pyrimidone ring of 6g formed a pi-pi interaction with the phenyl ring of Tyr99, and the carbonyl group in the P1 moiety formed multiple hydrogen bonds to Ser214 and Trp215. These results showed that isoxazolo[5,4-d]pyrimidin-4(5H)-one is an attractive scaffold for designing novel factor Xa inhibitors and 4-carbonyl substituted phenyl ring could be used as novel S1 binding element. (C) 2014 Elsevier Ltd. All rights reserved.
引用
收藏
页码:492 / 495
页数:4
相关论文
共 33 条
[1]   Factor Xa or thrombin: is factor Xa a better target? [J].
Ansell, J. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 :60-64
[2]   Venous Thromboembolism A Public Health Concern [J].
Beckman, Michele G. ;
Hooper, W. Craig ;
Critchley, Sara E. ;
Ortel, Thomas L. .
AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 2010, 38 (04) :S495-S501
[3]   DU-176b, a potent and orally active factor Xa inhibitor:: in vitro and in vivo pharmacological profiles [J].
Furugohri, T. ;
Isobe, K. ;
Honda, Y. ;
Kamisato-Matsumoto, C. ;
Sugiyama, N. ;
Nagahara, T. ;
Morishima, Y. ;
Shibano, T. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2008, 6 (09) :1542-1549
[4]  
HARA T, 1995, THROMB HAEMOSTASIS, V74, P635
[5]   In vivo rodent micronucleus assay: protocol, conduct and data interpretation [J].
Krishna, G ;
Hayashi, M .
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2000, 455 (1-2) :155-166
[6]   Structure-based design of novel guanidine/benzamidine mimics: Potent and orally bioavailable factor Xa inhibitors as novel anticoagulants [J].
Lam, PYS ;
Clark, CG ;
Li, RH ;
Pinto, DJP ;
Orwat, MJ ;
Galemmo, RA ;
Fevig, JM ;
Teleha, CA ;
Alexander, RS ;
Smallwood, AM ;
Rossi, KA ;
Wright, MR ;
Bai, SA ;
He, K ;
Luettgen, JM ;
Wong, PC ;
Knabb, RM ;
Wexler, RR .
JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (21) :4405-4418
[7]  
Lau DH, 2010, EXPERT REV CARDIOVAS, V8, P941, DOI [10.1586/erc.10.61, 10.1586/ERC.10.61]
[8]  
Leadley Robert J. Jr., 2001, Current Topics in Medicinal Chemistry, V1, P151
[9]   Developments in Factor Xa Inhibitors for the Treatment of Thromboembolic Disorders [J].
Lee, Yu-Kai ;
Player, Mark R. .
MEDICINAL RESEARCH REVIEWS, 2011, 31 (02) :202-283
[10]   Triggers, targets and treatments for thrombosis [J].
Mackman, Nigel .
NATURE, 2008, 451 (7181) :914-918